Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times

British Journal of Ophthalmology

Volumn 100, Issue 11, 2016, Pages 1494-1498

  Fauser, Sascha ^a   Muether, Philipp S ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Macula; Neovascularisation; Pharmacology; Retina; Treatment Medical

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; AQUEOUS HUMOR; ARTICLE; CENTRAL RETINAL VOLUME; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIMIT OF QUANTITATION; MALE; PRIORITY JOURNAL; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TISSUE LEVEL; TREATMENT DURATION; VERY ELDERLY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; AQUEOUS HUMOR; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84959421514     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-308264     Document Type: Article

References (12)

1. CATT Research Group Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908
2. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF-A trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-48
3. Muether PS, Hermann MM, Dröge K, et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 2013; 156: 989-93.e2
4. Muether PS, Hermann MM, Viebahn U, et al. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 2012; 119: 2082-6
5. Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 2014; 158: 532-6
6. Saunders DJ, Muether PS, Fauser S. A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab. Br J Ophthalmol 2015; 99: 1554-9
7. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012; 32: 434-57
8. Muether PS, Hoerster R, Hermann MM, et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013; 251: 453-8
9. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-9
10. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112: 806-16
11. Noma H, Funatsu H, Mimura T, et al. Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2008; 18: 1017-19
12. Mantel I, Gianniou C, Dirani A. Conversion to Aflibercept Therapy Versus Continuing with Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration Dependent on Monthly Ranibizumab Treatment. Retina 2016; 36: 53-8